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Abstract: Some 10–50% of Lynch-suspected cases with abnormal immunohistochemical (IHC) staining
remain without any identifiable germline mutation of DNA mismatch repair (MMR) genes. MMR
proteins form heterodimeric complexes, giving rise to distinct IHC patterns when mutant. Potential
reasons for not finding a germline mutation include involvement of an MMR gene not predicted
by the IHC pattern, epigenetic mechanism of predisposition, primary mutation in another DNA
repair or replication-associated gene, and double somatic MMR gene mutations. We addressed
these possibilities by germline and tumor studies in 60 Lynch-suspected cases ascertained through
diagnostics (n = 55) or research (n = 5). All cases had abnormal MMR protein staining in tumors but
no point mutation or large rearrangement of the suspected MMR genes in the germline. In diagnostic
practice, MSH2/MSH6 (MutS Homolog 2/MutS Homolog 6) deficiency prompts MSH2 mutation
screening; in our study, 3/11 index individuals (27%) with this IHC pattern revealed pathogenic
germline mutations in MSH6. Individuals with isolated absence of MSH6 are routinely screened
for MSH6 mutations alone; we found a predisposing mutation in MSH2 in 1/7 such cases (14%).
Somatic deletion of the MSH2-MSH6 region, joint loss of MSH6 and MSH3 (MutS Homolog 3)
proteins, and hindered MSH2/MSH6 dimerization offered explanations to misleading IHC patterns.
Constitutional epimutation hypothesis was pursued in the MSH2 and/or MSH6-deficient cases plus
38 cases with MLH1 (MutL Homolog 1)-deficient tumors; a primary MLH1 epimutation was identified
in one case with an MLH1-deficient tumor. We conclude that both MSH2 and MSH6 should be
screened in MSH2/6- and MSH6-deficient cases. In MLH1-deficient cases, constitutional epimutations
of MLH1 warrant consideration.
Keywords: Lynch syndrome; DNA mismatch repair; colorectal cancer; deep sequencing
1. Introduction
Colorectal cancer (CRC) is the third most common cancer type globally and one of the leading
causes of death [1]. Lynch syndrome (LS) is the most prevalent form of hereditary predisposition to
CRC and accounts for 2–3% of all CRCs [2]. LS patients also have frequent extracolonic cancers, notably
endometrial cancer in females [2]. Heterozygous pathogenic variants in the DNA mismatch repair
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(MMR) genes, namely MLH1, MSH2, MSH6, and PMS2 and less frequently, deletions in the 3′ end
of EPCAM cause predisposition to LS [3]. Other MMR genes may contribute to cancer susceptibility
with lower penetrance (MLH3) or predispose to polyposis (MSH3, MLH3) [4,5]. It is generally thought
that a ‘second hit’, a somatic mutation, in the wild-type allele of the affected MMR gene is required
for triggering tumorigenesis. There is, however, some evidence for haploinsufficiency for the MMR
genes [6].
Based on two-hit inactivation, absence of protein expression of selected MMR gene(s) by
immunohistochemical (IHC) analysis helps to direct gene testing for the purposes of LS diagnostics [7].
The human MMR mechanism functions via two interacting base proteins, MutL and MutS. Four MutL
proteins (MLH1, MLH3, PMS1 and PMS2) and five MutS proteins (MSH2, MSH3, MSH4, MSH5,
MSH6) have been recognized to date. Out of these, MLH1 and MSH2 are considered primary dimers,
which dimerize with any of the secondary dimers in the same protein family. The absence of cellular
primary dimer is typically followed by proteolytic degradation of its respective secondary dimers.
Thus, IHC staining of tumor samples with MSH2 mutations display negative nuclear staining for
both MSH2 and MSH6, and tumors from individuals with MLH1 mutations lack MLH1 and PMS2
proteins. In contrast, tumors of patients with MSH6 mutations exhibit negative nuclei for only MSH6,
and isolated absence of PMS2 proteins points to PMS2 mutations.
The so-called universal tumor screening for LS based on IHC and/or microsatellite instability (MSI)
analysis is nowadays recommended for all patients diagnosed with CRC or endometrial cancer [8,9].
IHC testing on CRC tumors has a sensitivity of 94% and specificity of 88% in the identification of
patients with LS [10]. Concordance between IHC and MSI is very high in CRCs [10,11], but often lower
in extracolonic tumors [6].
While IHC-based strategies generally perform well in pre-screening of LS [10,11], they are not 100%
accurate. For instance, somatic MMR gene alterations, related or unrelated to the predisposing MMR
gene mutations may confuse diagnostics. Somatic hypermethylation of the MLH1 promoter [12], MMR
gene mutations secondary to polymerase proofreading defects [13], and double somatic MMR gene
mutations [14] are examples of mechanisms that can mislead interpretations of germline mutations.
We, here, address these possible mechanisms by studies of constitutional and tumor tissues in a series
of 60 LS-suspected cases with abnormal IHC but no germline mutation in the MMR genes expected to
be involved according to the IHC pattern of tumors.
2. Results
2.1. Clinicopathological Characteristics and Study Design
Our study consisted of 60 suspected LS patients from Finland who were ascertained as described
in Section 4 as well as in Figure 1. All patients were mutation negative by diagnostic testing carried
out on the primary-suspect MMR gene. Clinical and molecular patient data are listed in Table S1.
The average age at onset for the first LS-associated cancer (typically CRC) in all patients was 51.6 years
(SD = 11.7). For MLH1, MSH2, and MSH6-deficient cohorts separately, the average ages at onset were
53.6 (SD = 13.2), 47.3 (SD = 7.7), and 50.6 (SD = 6.8), respectively.
To unravel the molecular basis of abnormal MMR protein expression in patients, three alternative
scenarios were considered (Figure 1). First, the predisposing alteration may not be genetic but
epigenetic. Second, the IHC pattern may not always predict the correct MMR gene. Third, absent
MMR protein may be secondary to alterations in other DNA repair- or replication-related genes,
or entirely somatic in origin. In the MLH1-deficient group, we concentrated on MLH1 epimutations
alone. This was because our MLH1-deficient cases originated from the time-period when exclusion of
somatic MLH1 hypermethylation was not yet part of the routine diagnostic scheme. Not knowing
which cases were possibly explained by somatic MLH1 methylation and not having tumor tissues
available, further molecular dissection was not meaningful. A more comprehensive evaluation was
possible for the MSH2- and MSH6-deficient cases. Laboratory assays conducted are shown in Figure 1
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and case by case in Table S1. DNA methylation alterations were investigated by methylation-specific
multiplex ligation-dependent probe amplification (MS-MLPA). Genetic mutation screens included
panel sequencing by NimbleGen’s Comprehensive Cancer Panel (CCP) for point mutations and
multiplex ligation-dependent probe amplification (MLPA) for exon-level deletions and duplications.
CCP covers the entire coding regions and flanking exon/intron borders of the MMR genes plus 574
other cancer-relevant genes. In selected cases, genome-wide sequencing (such as whole-genome
sequencing in the research families F70 and F88) was performed to be able to detect, for example,
complex rearrangements.
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All study subjects had abnormal IHC without any germline mutation in the primary MMR gene 
suspected based on the IHC pattern. Research questions addressed and assays used to disentangle 
the mechanisms behind abnormal IHC are listed at the bottom of the flow chart in Figure 1.  
2.2. MLH1 Cohort 
One index case out of 38 (3%) was found positive for an apparent constitutional 
hypermethylation of MLH1. In this patient (MLH1_14 in Table S1), all five HhaI sites tested from the 
MLH1 promoter region and flanking area showed hypermethylation (Figure 2). Methylation dosage 
(Dm) values ranged between 0.44 and 0.52, compatible with monoallelic methylation. The so-called 
Deng C region is the most important regarding transcriptional silencing by methylation [15,16]. No 
DNA sequence alterations were found in the immediate promoter region by Sanger sequencing, and 
no large rearrangements were detected by MLPA, suggesting a primary type of constitutional 
epimutation. 
Figure 1. Flow chart of this investigation. Abbreviations: LSRFi, Hereditary Colorectal Cancer Registry
of Finland; IHC, immunohistochemical; MS-MLPA, methylation-specific multiplex ligation-dependent
probe amplification; CNV, copy number variant; CCP, Comprehensive Cancer Panel; WGS, genome
sequenci g; WES, exome seque cing.
All study subjects had abnormal IHC without any germline mutation in the primary MMR gene
suspected based on the IHC pattern. Research questions address d and assays used to disentangle th
mechanisms b hind abnormal IHC are li ted at the bottom of the flow chart in Figure 1.
2.2. MLH1 Cohort
One index case out of 38 (3%) was found positive for an apparent constitutional hypermethylation
of MLH1. In this patient (MLH1_14 in Table S1), all five HhaI sites tested from the MLH1 promoter
region and flanking area showed hypermethylation (Figure 2). Methylation dosage (Dm) values
ranged between 0.44 and 0.52, compatible with monoallelic methylation. The so-called Deng C
region is the most important regarding transcriptional silencing by methylation [15,16]. No DNA
sequence alterations were found in the immediate promoter region by Sanger sequencing, and no large
rearrangements were detected by MLPA, suggesting a primary type of constitutional epimutation.
Cancers 2020, 12, 1853 4 of 15
Cancers 2020, 12, 1853 4 of 15 
 
 
Figure 2. Details of constitutional epimutation affecting the MLH1 promoter in case MLH1_14. (A) 
MS-MLPA tracing of the MLH1 promoter region including five methylation-sensitive sites monitored 
in the assay. The presence of a peak at a methylation-sensitive site indicates methylation, the degree 
of which Dm, the methylation dosage ratio, can be calculated from the peak areas, whereas the absence 
of a peak indicates no methylation (the remaining peaks shown in the figure represent reference 
genomic areas lacking HhaI sites). All five methylation-sensitive sites (arrows) are methylated in 
leukocyte-derived DNA from MLH1_14 and unmethylated in a healthy control. Normalized Dm 
values around 0.5 suggest that one allele is likely to be fully methylated and the other allele 
unmethylated in MLH1_14. (B) Diagram of the MLH1 promoter region showing the positions of the 
methylation-sensitive sites (lollipops) relative to the translation start codon ATG (for initiating 
methionine). From Deng et al. [15], areas A–D are depicted, and area C closely correlates with 
expressional silencing. Bent arrow indicates transcription start according to Deng et al. [15]. 
2.3. MSH2 Cohort 
2.3.1. Consecutive MSH2-Deficient Cases from Diagnostics 
Genetic variants are conventionally divided into five categories of pathogenicity based on 
characteristics of the variant as well as the clinical and family features [3]. Variants belonging to 
classes 1 (benign) and 2 (likely benign) are considered harmless. Class 3 is assigned to variants of 
uncertain significance (VUS). Classes 4 (likely pathogenic) and 5 (pathogenic) indicate that the variant 
is deleterious, and clinical management protocols recommended for LS should be undertaken. 
Among the ten consecutive MSH2-deficient cases available for this investigation, heterozygous VUS 
alterations in MSH2 were originally diagnosed for two. Case MSH2_3 had c.998G>A, p.(Cys333Tyr) 
variant, whereas case MSH2_10 showed c.1805T>C, p.(Leu602Pro) variant (reference sequence 
NM_000251.3) (Table S2). For the former variant, new data that became available while this study 
was ongoing, justified a shift from pathogenicity class 3 to class 5 upon assessment by the InSiGHT 
expert group, thus explaining MSH2-deficiency in this patient. The latter variant remains to be 
classified as a VUS, leaving the basis of MSH2-deficiency in MSH2_10 unsettled. 
By MS-MLPA, no constitutional epimutations (of MSH2 or MSH6 which were the most relevant 
genes in this context) were detected. To address the hypothesis of MSH6-associated predisposition 
in the nine MSH2-deficient cases that remained without a molecular explanation, MSH6 was screened 
by CCP sequencing. A pathogenic germline mutation was discovered in one case: MSH2_9, the index 
individual from F286, showed a heterozygous MSH6 c.3013C>T, p.(Arg1005Ter) nonsense mutation 
(reference sequence NM_000179.2) (Figure 3A,B; Table S2). No obvious second hit (somatic mutation 
or loss of heterozygosity (LOH)) in MSH6 was detectable in the patient’s tumor tissue (Table 1). 
Details of consti utional epimutation affecting the MLH1 pr moter in case MLH1_14.
(A) S-MLPA tracing of the MLH1 promoter region including five methylation-sensitive sites i
.
hich Dm, the methylation dosage ratio, can be c lculated from the peak ar as, w reas th
absence of a peak i dicates no methylation (the rem ining peaks shown in th figure present
reference genomic areas lacking HhaI sites). All five methylation-sensitive sites (arrows) are methylated
in leukocyt -derived DNA from MLH1_14 and unmethylated in a healthy control. Normalized
Dm values around 0.5 suggest that one allele is likely to be fully methylated and the t r ll l
et l te i L 1_14. (B) Diagram of the MLH1 promoter region showing the positions of
the methylatio -sensitive sites (lollipops) relative to the translation start codon ATG (for i itiati g
ethionine). From Deng et al. [15], areas – are epicte , an area closely correlates ith
expressional silencing. Bent arro indicates transcription start according to eng et al. [15].
2.3. MSH2 Cohort
2.3.1. Consecutive MSH2-Deficient Cases from Diagnostics
Genetic variants are conventionally divided into five categories of pathogenicity based on
characteristics of the variant as well as the clinical and family features [3]. Variants belonging to
classes 1 (benign) and 2 (likely benign) are considered harmless. Class 3 is assigned to variants of
uncertain significance (VUS). Classes 4 (likely pathogenic) and 5 (pathogenic) indicate that the variant
is deleterious, and clinical management protocols recommended for LS should be undertaken. Among
the ten consecutive MSH2-deficient cases available for this investigation, heterozygous VUS alterations
in MSH2 were originally diagnosed for two. Case MSH2_3 had c.998G>A, p.(Cys333Tyr) variant,
whereas case MSH2_10 showed c.1805T>C, p.(Leu602Pro) variant (reference sequence NM_000251.3)
(Table S2). For the former variant, new data that became available while this study was ongoing,
justified a shift from pathogenicity class 3 to class 5 upon assessment by the InSiGHT expert group,
thus explaining MSH2-deficiency in this patient. The latter variant remains to be classified as a VUS,
leaving the basis of MSH2-deficiency in MSH2_10 unsettled.
By MS-MLPA, no constitutional epimutations (of MSH2 or MSH6 which were the most relevant
genes in this context) were detected. To address the hypothesis of MSH6-associated predisposition in
the nine MSH2-deficient cases that remained without a molecular explanation, MSH6 was screened by
CCP sequencing. A pathogenic germline mutation was discovered in one case: MSH2_9, the index
individual from F286, showed a heterozygous MSH6 c.3013C>T, p.(Arg1005Ter) nonsense mutation
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(reference sequence NM_000179.2) (Figure 3A,B; Table S2). No obvious second hit (somatic mutation
or loss of heterozygosity (LOH)) in MSH6 was detectable in the patient’s tumor tissue (Table 1).
Interestingly, somatic mutation analysis by VarScan 2 revealed a nonsense mutation in MSH2,
c.2528delG, p.(Cys843fs), with variant allele frequency (VAF) of 11% (Table 1; Table S3). This somatic
mutation of MSH2, combined with presumed inactivation of the wild-type allele of MSH2 by a
mechanism that remained unknown, likely contributed to the absent MSH2 by IHC.
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mutation of the MSH6-deficient case MSH6_5 against the gene and protein structure of MSH2.
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Table 1. Summary of germline and somatic alterations in patients from the MSH2-deficient cohort with
tumor samples available for molecular studies.
Case ID IHC Pattern Germline Mutation Second Hit
Additional Somatic
Alterations Relevant for
IHC Pattern
MSH2_9/F286 II.2 MSH2-, MSH6- MSH6 c.3013C>T, None identified MSH2 c.2528delG,
p.(Arg1005Ter) * p.(Cys843fs)
F70 III.6 (index) MSH2-, MSH6- MSH6 c.3103C>T, MSH2-KCNK12-MSH6
deletion
(MSH2-KCNK12-MSH6
deletion)p.(Arg1035Ter)*
F70 II.5 MSH6- MSH6 c.3103C>T, MSH6 c.2932C>T, Not applicable
p.(Arg1035Ter)* p.(Gln978Ter)
F88 IV.4 MSH2-, MSH6- MSH6c.1052+2023_c.3557-179, MSH6 c.3261dupC, MSH3 c.1148delA,
p.(Asp1058Alafs) p.(Phe1088Leufs) * (pLys383Argfs)
An asterisk (*) denotes the variants present in the InSiGHT database.
Case MSH2_1 showed no germline mutation of MSH6 or other MMR genes. The availability of a
tumor sample (CRC) from this patient made it possible to test the hypothesis that MSH2-deficiency
resulted from two somatic mutations (“Lynch-like syndrome” [14]). VarScan2 analysis identified
a somatic MSH2 mutation, c.1627G>A, p.(Asp543Asn) (VAF 12%) (Table S3) which was classified
as likely pathogenic by Varsome. With relaxed criteria (p < 0.05), another somatic MSH2 mutation,
c.2767G>A, p.(Val923Ile), VAF 10%, was present; its pathogenic significance is unknown (VUS by
Varsome evaluation). Additionally, a somatic mutation in MSH6 and two somatic mutations in MLH1
were detected as well, all missense type and occurring with allele frequencies less than 10%. Sanger
sequencing of tumor DNA revealed somatic polymerase proofreading domain mutations (for details,
see Section 2.5) which possibly contributed to the multiple somatic MMR gene mutations observed.
Collectively, the somatic mutation data justify interpretation of MSH2_1 as a plausible double somatic
MMR gene mutation case.
2.3.2. Families from the Hereditary Colorectal Cancer Registry of Finland (LSRFi)
F70
Sequencing of leukocyte-derived normal samples from three individuals from F70 (II.5, III.3, III.6)
revealed a MSH6 c.3103C>T, p.(Arg1035Ter) nonsense mutation (Figure 3A,B; Table S2). The mutation
affects exon 4, near the start of the lever domain, resulting in the loss of the remaining protein
structure. The mutation’s allele frequency is 8.402 × 10−6, only found from a non-Finn carrier in
the gnomAD database. The mutation has been registered to the InSiGHT database 12 times, being
diagnosed in Swedish, Danish, and Dutch patients. The InSiGHT database classifies the variant as
class 5. The nonsense mutation was verified with Sanger sequencing and all four tested F70 members
were found to be carriers of the mutation (Figure 3A).
Tumors from members of F70 showed variable IHC staining patterns, including MSH6- with
positive staining for MSH2 (CRC from II.5), MSH2+, MSH6+ (stomach cancer from III.3), and MSH2-,
MSH6- (adenoma from III.6) (Table S1). By CCP screen, the tumor of F70 II.5 revealed a nonsense
mutation in MSH6: c.2932C>T, p.(Gln978Ter), VAF 22%, serving as a likely “second hit” (Table 1;
Table S3). MS-MLPA and MLPA analyses of the normal and tumor samples gave a normal result;
there was no observable genomic rearrangement or hypermethylation of MSH6 in this sample.
By MLPA, the tumor sample of F70 III.6 exhibited a heterozygous deletion in MSH2-KCNK12-MSH6
region in chromosome 2 presumably involving the wild-type allele (Table 1; Figure S1). The observation
was further supported by LOH analysis of deep sequencing data, which displayed LOH of the wild-type
allele at the site of the germline mutation. Thus, somatic deletion of the MSH2-KCNK12-MSH6 region
provided a “second hit” to accompany the MSH6 germline mutation, and additionally, a mechanism
for MSH2 inactivation to explain the IHC pattern (although we could not identify a second somatic
Cancers 2020, 12, 1853 7 of 15
“hit”, genetic or epigenetic, in MSH2). Tumor samples from F70 showed no instability at the MSH3-A8
coding region microsatellite sequence.
F88
The index of F88 (F88 IV.4) was found to have a 2261 bp deletion (c.1052+2023_c.3557-179,
pAsp1058Alafs) covering exons 5 and 6 and part of the flanking introns of MSH6 (Figure 3A,B; Table S2).
Subsequent MLPA analysis was used to verify the deletion. According to the InSiGHT MMR gene
variant classification criteria (2016), large deletions in MMR genes are considered class 5, pathogenic.
Incidentally, the sister of the index case (F88 IV.6) was found to be a carrier of MLH1 exon
16 deletion, based on a genetic test performed in a diagnostic laboratory (Figure 3A). We subsequently
investigated the index case (F88 IV.4) and the mother of the sisters (F88 III.5) for MLH1 exon 16 deletion
by MLPA, and the result was negative in the index case and positive in the mother. The mother
was also tested for the 2261 bp deletion of MSH6 and the result was negative. Thus, F88 had two
branches with a different genetic deletion. The MLH1 exon 16 deletion originated from the index
case’s mother who transmitted it to the index case’s sister. The MSH6 exon 5–6 deletion present in the
index case may represent de novo alteration, but it is also possible that her father (F88 III.4) had the
same deletion; the father’s carrier status could not be determined because no sample was available for
testing (Figure 3A).
Endometrial cancer from F88 IV.4 showed MSH2- and MSH6- by IHC. For the second hit analysis,
we attempted calculating LOH at the mutation site in the index case’s tumor sample by MLPA, but it
was impossible due to poor tumor sample quality. CCP deep sequencing outputs detected no change
in the coverage of MSH6 exons in the tumor. However, a somatic frameshift mutation affecting the
coding MSH6-C8 microsatellite sequence was detected: c.3261dupC, p.(Phe1088Leufs) with VAF of
29% (Table 1; Table S3). The observation was verified by Sanger sequencing (Figure S2A). The InSiGHT
database classifies MSH6 p.(Phe1088Leufs) as class 5, pathogenic.
Inspired by the finding of a c.3261dupC, p.Phe1088Leufs frameshift mutation in the coding
MSH6-C8 microsatellite in F88 IV.4, coding microsatellite sequences in MSH2 and MSH3 were analyzed
by CCP and Sanger sequencing, respectively, in an attempt to seek explanations for the observed
IHC pattern (MSH2-deficiency). No mutations were observed in the MSH2-A7 microsatellite in F88
(or any other cases with MSH2-deficient tumors in our study series). Sanger sequencing of MSH3-A8
in the tumor from F88 IV.4 showed an indication of deletion of adenine, predicted to result in a
frameshift mutation c.1148delA, p.(Lys383Argfs) (Table 1; Figure S2B). No MSH2 or MSH6 promoter
hypermethylation was observed in the tumor from F88 IV.4.
2.4. MSH6 Cohort
MS-MLPA revealed no constitutional epimutations of MSH6 or MSH2 among the seven patients
with MSH6-deficient tumors. When screened for MSH2 germline mutations by panel sequencing
(CCP), one case (MSH6_5) was found to have a truncating mutation in MSH2 exon 1: c.110delT,
p.(Phe37Serfs*27) (Figure 3A,C; Table S2). Hence, the frequency of MSH2 germline mutations in
patients with MSH6-deficient tumors was 1/7 (14%). Unfortunately, no tumor tissue was available from
MSH6_5 for studies of MSH2 second hit status and possible somatic alterations of MSH6 to explain the
IHC pattern.
2.5. Polymerase δ and
Cancers 2020, 12, 1853  7 of 15 
 
F88 
The  index  of  F88  (F88  IV.4) was  found  to  have  a  2261  bp deletion  (c.1052+2023_c.3557‐179, 
pAsp1058Alafs) covering exons 5 and 6 and part of the flanking introns of MSH6 (Figure 3A,B; Table 
S2). Subsequent MLPA analysis was used  to verify  the deletion. According  to  the  InSiGHT MMR 
gene  variant  classification  criteria  (2016),  large  deletions  in MMR  genes  are  considered  class  5, 
pathogenic. 
Incidentally, the sister of the index case (F88 IV.6) was found to be a carrier of MLH1 exon 16 
deletion, based on a genetic test performed in a diagnostic laboratory (Figure 3A). We subsequently 
investigated  the  index  case  (F88  IV.4) and  the mother of  the  sisters  (F88  III.5)  for MLH1 exon 16 
deletion by MLPA, and  the result was negative  in  the  index case and positive  in  the mother. The 
mother was also tested for the 2261 bp deletion of MSH6 and the result was negative. Thus, F88 had 
two branches with a different genetic deletion. The MLH1 exon 16 deletion originated from the index 
case’s mother who transmitted it to the index case’s sister. The MSH6 exon 5–6 deletion present in 
the index case may represent de novo alteration, but it is also possible that her father (F88 III.4) had 
the same deletion; the father’s carrier status could not be determined because no sample was available 
for testing (Figure 3A). 
Endometrial  cancer  from  F88  IV.4  showed MSH2‐  and MSH6‐  by  IHC.  For  the  second  hit 
analysis, we attempted calculating LOH at  the mutation site  in  the  index case’s  tumor sample by 
MLPA, but  it was  impossible due  to poor  tumor  sample quality. CCP deep  sequencing outputs 
detected no change  in  the coverage of MSH6 exons  in  the  tumor. However, a somatic  frameshift 
mutation  affecting  the  coding  MSH6‐C8  microsatellite  sequence  was  detected:  c.3261dupC, 
p.(Phe1088Leufs) with VAF  of  29%  (Table  1; Table  S3). The  observation was  verified  by  Sanger 
sequencing  (Figure  S2A).  The  InSiGHT  database  classifies  MSH6  p.(Phe1088Leufs)  as  class  5, 
pathogenic. 
Inspired by  the  finding of  a  c.3261dupC, p.Phe1088Leufs  frameshift mutation  in  the  coding 
MSH6‐C8  microsatellite  in  F88  IV.4,  coding  microsatellite  sequences  in MSH2  and MSH3  were 
analyzed by CCP and Sanger sequencing, respectively,  in an attempt  to seek explanations  for  the 
observed IHC pattern (MSH2‐deficiency). No mutations were observed in the MSH2‐A7 microsatellite 
in F88 (or any other cases with MSH2‐deficient tumors  in our study series). Sanger sequencing of 
MSH3‐A8 in the tumor from F88 IV.4 showed an indication of deletion of adenine, predicted to result 
in  a  frameshift mutation  c.1148delA,  p.(Lys383Argfs)  (Table  1;  Figure  S2B). No MSH2  or MSH6 
promoter hypermethylation was observed in the tumor from F88 IV.4. 
2.4.  SH6 Cohort 
S‐ LPA revealed no constitutional epi utations of  SH6 or  SH2 a ong the seven patients 
with  SH6‐deficient  tu ors.  hen  screened  for  SH2 ger line  utations by panel  sequencing 
(CCP), one  case  ( SH6_5) was  found  to have a  truncating  utation  in  SH2 exon 1:  c.110delT, 
p.(Phe37Serfs*27)  (Figure  3A,C; Table S2). Hence,  the  frequency of  SH2 ger line  utations  in 
patients with MSH6‐deficient tumors was 1/7 (14%). Unfortunately, no tumor tissue was available 
from MSH6_5  for studies of MSH2 second hit status and possible somatic alterations of MSH6  to 
explain the IHC pattern. 
. .       Ɛ Mutation Analysis 
Reduced MMR protein  expression  can  be  observed  in patients with POLD1/E proofreading 
mutations [13]. As CCP does not include the POLD1 and POLE genes, we screened the mutational 
hotspot exons (POLD1 exon 11 and POLE exons 9 and 13) by Sanger sequencing of the constitutional 
and  tumor  tissues  from  the  index  individuals  from our MSH2‐  and MSH6‐deficient  cohorts. No 
pathogenic  or  likely  pathogenic mutations  (according  to VarSome  predictions  [17]) were  found 
except  for  one  case:  a  somatic  nonsense  variant  in  POLD1  exon  11,  c.1453C>T,  p.(Gln485Ter) 
(reference sequence NM_001256849.1) was detected  in case MSH2_1  (Figure S3A). This variant  is 
predicted pathogenic  by  the VarSome database. Additionally, MSH2_1  revealed  two  variants  of 
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NM_001256849.1) was detected in case MSH2_1 (Figure S3A). This variant is predicted pathogenic
by the VarSome database. Additionally, MSH2_1 revealed two variants of unknown significance
(VUS) in POLE exon 13: c.1324G>A, p.(Glu442Lys), and c.1332G>A, p.(Met444Ile) (reference sequence
NM_006231.4) (Figure S3B).
3. Discussion
We investigated 60 LS-suspected cases whose cancer susceptibility was unexplained from previous
studies. Among 57 index cases examined, a molecular explanation was found for six. The three
possible mechanistic scenarios proposed (Section 2.1.; Figure 1) were variably involved. Constitutional
epimutation explained one case (MLH1-14) from the MLH1-deficient group (1/38, 3%). Germline
mutation in an MMR gene not predicted by the IHC pattern accounted for three cases (MSH2_9/F286
II.2, F70 III.6, and F88 IV.4) from the MSH2-deficient group (3/11, 27%) and one case (MSH6_5) from
the MSH6-deficient group (1/7, 14%). Double somatic MSH2 mutations provided a likely explanation
for one MSH2-deficient case (MSH2_1). Finally, a revised classification (from class 3 to class 5) of a
previously detected MSH2 variant established the basis of cancer predisposition for one MSH2-deficient
case (MSH2_3).
In pre-screening for LS, patients with absent MSH2 and/or MSH6 protein in tumor tissue constitute
the most important group with germline mutations expected, since most consecutive cases lacking
MLH1 and PMS2 proteins are due to acquired MLH1 promoter methylation and isolated PMS2 loss is
rare [10,14]. Whenever IHC staining is negative for MSH2 and MSH6, it is customary in the diagnostic
setting to examine primarily the MSH2 gene. This is because MSH2 mutations outnumber MSH6
mutations, and the absence of MSH2 subsequently causes the degradation of cellular MSH6 because
MSH6 has no other dimerization partners apart from MSH2. A similar relationship exists between
MLH1 (primary protein) and PMS2 (secondary protein). Reliance on the instability of the secondary
protein when the primary protein is absent has led some to adopt a two-stain method to reduce IHC
costs: tumors are first stained with only MSH6 and PMS2, followed by MSH2 and MLH1 stains only
if MSH6 or PMS2, respectively, is absent. However, it was found that retained MSH6 expression in
the case of MSH2 germline or double somatic mutations is not uncommon [18], suggesting that the
regular four-stain method is preferable. Our investigation was based on the four-stain approach,
but this method, too, can be associated with non-canonical patterns, among which the absence of the
“wrong” MMR protein is especially challenging for diagnostic purposes. In our investigation 3/11 index
individuals with unexplained MSH2-deficient tumors (27%) revealed pathogenic germline variants in
MSH6, whereas 1/7 individuals with isolated absence of MSH6 (14%) showed a predisposing mutation
in MSH2. Similarly, in a study by Mensenkamp et al. [14], 2 of 17 patients (12%) with MSH2-deficient
tumors not explained by MSH2 or EPCAM mutations in the germline, had a predisposing mutation in
MSH6, and 1 of 5 unexplained cases with isolated MSH6 loss (20%) was attributable to a germline
mutation in MSH2. In another investigation [10], universal screening on 500 consecutive CRCs resulted
in the diagnosis of LS in 18 individuals, among which IHC findings were discordant with the germline
mutation results in two, including one with germline mutation in MSH6 although all four MMR
proteins were expressed, and one with a germline mutation in MSH6 (p.P1309SfsX11) although the
simultaneous lack of MSH2 and MSH6 proteins pointed to an MSH2 mutation.
Our study suggests that heterozygous germline MSH6 mutations may result in shortage and
aberrant function of MSH2 protein in several possible ways (Table 1) including: somatic deletion of the
MSH2-MSH6 region (as seen in F70 III.6), combined loss of MSH6 and MSH3 in somatic tissue (as seen
in F88 IV.4), or hindered MSH2 dimerization caused by the loss of the COOH-terminal interaction
domain in the truncated MSH6 proteins (applies to the germline MSH6 mutations of F70, F88, and F286,
and the MSH6 mutation reported by Hampel et al. [10]). Alternatively, the truncated MSH6 protein may
be able to bind to MSH2 and/or the DNA but lack any repair activity, thus competing with wild-type
MSH2 and MSH6. Our observations from F88 are analogous to findings reported by Morak et al. [19].
They described a case where a joint absence of MSH2 and MSH6 likely resulted from the simultaneous
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lack of MSH3 and MSH6 proteins, the binding partners of MSH2, due to germline and somatic
inactivating events. Their case exhibited a truncating heterozygous MSH6 variant and a truncating
heterozygous MSH3 variant in the germline, accompanied by LOH at the MSH6 region and somatic
heterozygous frameshift changes affecting MSH6-C8 and MSH3-A8 coding repeats. Our case (F88 IV.4)
showed a heterozygous germline mutation of MSH6 (genomic deletion of exons 5 and 6), combined
with somatic frameshift mutations MSH6-C8 and MSH3-A8 (Table 1).
Interestingly, despite the positive MSH2 staining of the tumor nuclei in MSH6_5, a germline
mutation of MSH2 p. (Phe37Serfs*27) was observed. MSH2 positivity could imply the absence of
a somatic “second hit”, which would also be compatible with stable microsatellites in the patient’s
endometrial cancer (Table S1). Experience from colorectal adenomas from patients with LS shows that
tumor development is possible when the wild-type allele is still present, and the respective protein is
expressed [20]. However, almost all CRCs and most endometrial carcinomas from LS patients lack
the protein corresponding to the gene mutant in the germline [6]. Furthermore, MSH6 negativity of
the tumor from MSH6_5 would technically indicate that a second hit in MSH2 would be expected.
Theoretically, two somatic mutations in MSH6 are possible. Unavailability of tumor tissue from this
patient unfortunately prevented a closer molecular investigation into this issue.
Constitutional epimutations of MLH1 (primary or secondary) and MSH2 (secondary to EPCAM
3′-end deletions) may account for a few percent of Lynch-suspected cases without conventional
genetic mutations despite abnormal IHC [21,22]. We found one case (MLH1_14) with an apparently
primary constitutional epimutation of MLH1 among 38 MLH1-, PMS2-deficient cases tested (3%).
We previously screened for constitutional epimutations a LS-suspected series ascertained in an
analogous manner and detected two positive cases (one primary and one secondary epimutation of
MLH1) among 22 cases examined (9%) [21]. Thus, the combined proportion of constitutional MLH1
epimutations in LS-suspected cases with MLH1-deficient tumors is 3/60 (5%). As case MLH1_14
illustrates, carriers of constitutional epimutations clinically resemble carriers of conventional genetic
mutations in MMR genes. However, family features and transmission pattern make a distinction [23].
Primary constitutional epimutations are seldom associated with any marked family history of cancer
(in agreement, MLH1_14 had no close relatives diagnosed with cancers of the LS spectrum) and are
usually not transmitted from parent to child. In contrast, secondary epimutations of MLH1 or MSH2
give rise to classical LS families and follow dominant Mendelian inheritance. MSH2 was not affected by
constitutional epimutations in our MSH2-deficient cases (EPCAM deletions were excluded by MLPA
from the outset). No constitutional epimutations of MSH6 or PMS2 were detected, which complies
with findings from another population [24]. Moreover, we found no evidence of hypermethylation of
MSH2 or MSH6 promoters as possible second hits in our MSH2- or MSH6-deficient tumors.
Occasionally, defective MMR protein expression in tumor tissue can be secondary to germline or
somatic mutation in another DNA repair or replication-associated gene, such as POLD1/E [13] or less
frequently, MUTYH [25]. In a study by Jansen et al. [13], 9 of 62 suspected LS patients (15%) with
abnormal IHC and/or MSI, but no identifiable MMR gene germline mutations, had germline (2/9)
or somatic (7/9) variants in the POLD1/E exonuclease domain. With one exception (case MSH6_7 with
insufficient DNA), we Sanger sequenced the mutational hotspots exons in POLD1/E (see Section 4)
in normal tissues from all our cases suspected of having MSH2 or MSH6 mutation, and in available
tumor tissues as well when relevant (a separate analysis was necessary since the CCP panel did
not include the POLD1/E genes). No germline POLD1/E mutations were found, but one pathogenic
variant and two VUS were observed in the tumor of MSH2_1. Morak et al. [25] screened MUTYH in
85 patients with abnormal IHC but no detectable germline mutations in MMR genes: one patient (1%)
showed a biallelic MUTYH germline mutation, accompanied by two somatic MSH2 mutations in a
MSH2/MSH6-deficient tumor (a sebaceous gland carcinoma). All our MSH2- and MSH6-suspect cases
were screened for germline MUTYH mutations as part of the CCP or whole-genome sequencing and
no positive cases were found. No obviously pathogenic germline mutations beyond the predisposing
MMR genes were identified in other DNA repair genes included in CCP (Table S2).
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Double somatic mutations of MMR genes may account for over half of MMR-deficient tumors
with neither somatic MLH1 promoter methylation nor germline mutations in MMR genes [14,26].
Results from our population-based investigation conducted earlier [26] are compatible with this notion,
but we could not formally test this possibility in the present series since the tumor tissues available to
us originated from germline mutation carriers. MSH2_1 with no germline mutation found constituted
the single exception. This case could be attributed to two somatic MSH2 mutations, provided that the
mutations affected different alleles (which cannot be resolved by our current assays).
Cohorts of consecutive LS-suspected cases which referred to clinical and basic genetic evaluation
over a decade constitute a strength of this investigation. Our comprehensive approach (genetic and
epigenetic) to identify the mechanisms of cancer predisposition in patients is another advantage.
The relatively modest numbers of cases in certain groups (e.g., the MSH6-deficient group) and poor
availability (and sometimes low quality due to formalin-fixed paraffin-embedded (FFPE)-origin)
of tumor samples are among the limitations. Lack of tumor tissues made a comprehensive evaluation
of MLH1-deficient cases impossible. In analogy to our observations from MSH2- and MSH6-deficient
cases, existing literature [14] suggests that small proportions of MLH1-deficient cases as well as cases
with solitary PMS2-deficiency exhibit germline mutations in MMR genes not predicted by the IHC
pattern. Another limitation caused by unavailability of tumor tissues was that we could not determine
the frequency of cases with double somatic mutations of MMR genes in our cohorts, as pointed
out above. Finally, the mechanisms we tested as possible explanations for altered MMR protein
expression are by no means all-inclusive. For example, microRNAs (e.g., overexpression of miR-155
can downregulate MLH1 and MSH2 [27]), and post-translational modifications (phosphorylation of
MSH2 increases resistance to ubiquitin-induced protein degradation [28]) have been identified as
somatic regulators of MMR gene expression.
4. Materials and Methods
4.1. Patients and Samples
Our patient material consisted of research and clinic-based cohorts (Figure 1; Table S1).
The patients represented putative LS families from diagnostic units across Finland (n = 55). In addition,
five individuals originated from two large families (F70 and F88) from the Hereditary Colorectal Cancer
Registry of Finland (LSRFi). The institutional review board of the Helsinki University Hospital approved
this study (466/E6/01). All the samples and patient information were obtained and used according
to the guidelines of this approval and following a written consent from the patients. The National
Supervisory Authority for Welfare and Health (Dnro 1272/04/044/07 and Dnro 10741/06.01.03.01/2015)
approved the collection of archival specimens.
The conventional diagnostic screening protocol consisted of IHC staining of tumor tissues for
MLH1, PMS2, MSH2, and MSH6 proteins, occasionally supplemented with MSI analysis, which were
followed by Sanger sequencing of the coding regions and immediate exon/intron borders of the gene
primarily suspected to be affected in each case based on the IHC pattern [7]. An accredited diagnostic
laboratory at Helsinki University Hospital (HUSLAB), highly experienced in such analyses, performed
the IHC, MSI, and sequencing assays. If no pathogenic or likely pathogenic germline alteration was
found, MLPA was performed in our research laboratory. Cases/families remaining mutation-negative
after all these assays were eligible for this study. Fresh frozen and/or formalin-fixed paraffin-embedded
(FFPE) specimens of tumor and matching normal tissues were collected from pathology departments
of different hospitals and used for IHC analysis and DNA extraction. Areas with pure normal or high
tumor percentages, with minimal intervening stroma or inflammatory cells, were selected and verified
histologically and subsequently dissected out for DNA preparation. DNA was extracted from EDTA
blood or FFPE–derived tissues of the patients according to the protocols used by Renkonen et al. [29]
and Isola et al. [30].
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4.2. Immunohistochemical Staining (IHC)
IHC staining analyses were conducted on FFPE samples by HUSLAB Laboratory of Pathology
as described by Renkonen et al. [29]. The analyses included positive controls and each slide was
required to have sufficient representation of normal and malignant tissue as tests for analysis coherence.
Antibodies used were anti-MLH1 (clone G168-15; Pharmingen, San Diego, CA, USA), anti-MSH2 (clone
FE-11; Calmiochem/Oncogene Research, San Diego, CA, USA), anti-MSH6 (clone 44; Transduction
Laboratories, San Diego, CA, USA), and anti-PMS2 (clone 556415; BD Pharmingen, Franklin Lakes,
NJ, USA). Both MLH1 and MSH6 antibodies were full-length, monoclonal antibodies, whereas MSH2
antibody was monoclonal, raised against carboxyl-terminal fragment of the human MSH2 protein.
For visualization of the samples, EnVision+ System (DakoCytomation, Glostrump, Denmark) was
applied. A pathologist evaluated all samples in this study for nuclear MMR protein staining. If any of
the tumor cells displayed positive nuclear staining, the sample was considered positive for the tested
protein (as instructed by the International Collaborative Group on HNPCC).
4.3. Microsatellite Instability Analysis (MSI)
The tumors’ MSI status was determined using fluorescent markers BAT25 and BAT26,
and sometimes additionally D5S349, D2S123, and D17S250. MSI-high status required that at least one
of the mononucleotide repeat markers, BAT25 and BAT26, showed MSI [31].
4.4. MMR Gene Methylation Status
To determine the methylation status changes in the MMR genes of both normal and tumor samples,
MS-MLPA was performed by using the SALSA MLPA ME011-B3 probemix (MRC-Holland, Amsterdam,
Netherlands) according to the manufacturer’s instructions and as described in Gylling et al. [21].
4.5. MMR Gene Copy Number Status
To evaluate the possibility of copy number changes in the MMR genes, MLPA was applied. SALSA
MLPA P003-D1 and SALSA MLPA P072-C1 (MRC-Holland, Amsterdam, Netherlands) were used for
MLH1/MSH2 and MSH6, respectively. The probemixes used in (MS) MLPA include probes testing for
sample fragmentation and sufficient digestion.
Fragment analysis for both MS-MLPA and MLPA was carried out using on ABI3730xl DNA
Analyzer (Applied Biosystems, Foster City, CA, USA) at the Institute for Molecular Medicine of
Finland (FIMM) Technology Centre and analyzed on GeneMapper software version 5.0 (Thermo Fisher,
Waltham, MA, USA) and CoffalyserTM (MRC-Holland, Amsterdam, Netherlands).
4.6. Sanger Sequencing
To determine the possible loss of MMR gene expression in tumor tissue due to mutations in genes
encoding for polymerase
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ThruPLEX® DNA‐seq kit (Rubicom Genomics), KAPA HyperPlus kit (Roche, Basel, Switzerland), or 
Accel‐NGS  1S  Plus  (Swift  Biosciences, Ann Arbor, MI, USA) was  used  for  library  preparation. 
i s 9 an 13, as we l as POLD1 exon
11 i constitutional and tumor tissues using primers by Church et al. [32] and
Valle et al. [33], respectively.
Custom primers for microsatellite repeat sequences MSH6-C8 and MSH3-A8 were
designed using Primer3 software (bioinfo.ut.ee). Primers were as follows: MSH6-C8-F:
5′ GTGATGGTCCTATGTGTC 3′, MSH6-C8-R: 3′ CGTAATGCAAGGATGGCGT
5′, and MSH3-A8-F: 5′ ATGTGAAT CCCTAATCAAGCTGG 3′, MSH3-A8-R: 3′
GCA AG TTACC CAATGCC T AAA 5′.
4.7. Deep Sequencing and Variant Analysis
Whole genome sequencing was applied to leukocyte-derived DNA from three cases from the
research families (F70 and F88). The libraries were prepared using the ThruPLEX® DNA-seq kit
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(Rubicon Genomics, Ann Arbor, MI, USA) and run on Illumina HiSeq 2500 platform (San Diego,
CA, USA).
Sixteen normal samples and four matching tumor samples were analyzed using CCP. ThruPLEX®
DNA-seq kit (Rubicom Genomics), KAPA HyperPlus kit (Roche, Basel, Switzerland), or Accel-NGS 1S
Plus (Swift Biosciences, Ann Arbor, MI, USA) was used for library preparation. Roche/NimbleGen’s
SeqCap EX Exome Library v2.0 is an exome enrichment platform using biotinylated oligonucleotide
baits which are complementary to the exome targets. These baits hybridize to sequencing libraries
prepared from fragmented genomic DNA. CCP analysis uses 2.1 million overlapping probes to cover
578 cancer-associated genes. One tumor sample was processed with Twist Core Exome Kit and the
library were prepared using Twist EF library preparation protocol and run on NovaSeq S1 PE101.
FIMM Next Generation Sequencing service performed the primary (read preparation and quality
control) and secondary analysis (copy number variant (CNV) calls) on the samples to produce
ready-to-analyze whole genome sequencing (WGS) data. The sequencing data was analyzed by
in-house variant calling pipeline (VCP) versions v3.3 and v3.4. (WGS), v3.7b (exome sequencing (WES)),
3.6 and 3.7 (CCP). The VCP analysis includes quality control of raw reads pre- and post-alignment,
pre-processing for sequencing artifacts, alignment to human reference genome (GRCh37) with the
Burrows–Wheeler alignment (BWA) [34], and variant calling with SAMtools package [35]. Performance
characteristics of all deep sequencing experiments included in this study are given in Table S4.
Tertiary analysis was carried out with VarSeq® (v1.3.2, Golden Helix) and analyzed according
to the principles used by Olkinuora et al. [5]. Briefly, only high-quality (Phred-scale likelihood >70),
rare (variant allele frequency <0.003 in the ExAC and GnomAD databases), and nonsynonymous
variants (frameshift, stop gained/lost, missense, disrupting donor/acceptor site variants) were
considered. Additionally, only variants predicted tolerated by a maximum of 1 in silico software
(SIFT, PolyPhen2 HVAR, MutationTaster, MutationAssessor, FATHMM, and FATHMM MKL) were
taken for further analysis. Only variants affecting genes participating in DNA repair according to
Wood et al. [36] were considered.
4.8. Somatic Mutation Profiling
VarScan2 mutation detection algorithm version 2.3.2 was carried out by FIMM for identifying
somatic, non-synonymous mutations from the tumor-normal sample pairs. The following mutation
calling parameters were used: normal-purity 1, strand-filter 1, min coverage 8 and 6 (for normal and
tumor samples, respectively), minimum variant frequency 0.005, and somatic p-value 1. Annotation of
the mutations was done using SnpEff version 4.0 with the Ensembl v68 annotation database. Variants
with a somatic p-value less than 0.01 were selected for further analyses.
4.9. Loss of Heterozygosity (LOH) Analysis
LOH analysis for relevant MMR genes was based on the comparison of deep sequencing data
for paired tumor and normal samples [37] and was performed by VarSeq (GoldenHelix®, Bozeman,
MT, USA). We followed the thresholds set for putative and strict LOH in Ollikainen et al. [38]. When
reporting LOH data, putative and strict LOH are called LOH for simplicity.
5. Conclusions
Two main conclusions directly relevant for LS diagnostics can be drawn from our findings.
First, as the predisposing mutation was in MSH6 in 27% of index cases with MSH2-deficient tumors,
and in MSH2 in 14% of cases with solitary absence of MSH6, germline mutation analysis in such
cases should include both MSH2 and MSH6 and not just the gene primarily suspected from the IHC
pattern. Multigene panel sequencing, which is gradually replacing single-gene tests in LS diagnostics,
is expected to alleviate this problem. Panel testing would not be affected by misleading IHC patterns
since all main MMR genes (and other relevant cancer predisposition genes, too, as appropriate)
can be interrogated simultaneously. Second, in MLH1-deficient cases with no point mutations or
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large rearrangements of MLH1, the possibility of constitutional epimutations should be kept in
mind (5% frequency in the combined series of this and our previous investigation [21]). Although
constitutional epimutations are rare, awareness of their existence and unique characteristics, including
variable patterns of transmission, is important for a proper clinical management of the patients and
their relatives.
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in all cases sequenced, Table S3: Significant somatic mutations by VarScan2 analysis, Table S4: Performance
characteristics of the deep sequencing runs in this study.
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